Avanzanite Bioscience
Avanzanite Bioscience is a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases. The company aims to solve Europe's rare-disease medicines access gap by integrating commercial excellence, scientific expertise, and deep functional capability across market access, pricing, and reimbursement.
Leadership & Board
- Current Number of Employees
- 98
- Current LinkedIn Followers
- 6,018
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $32M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $32M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Avanzanite Bioscience LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Avanzanite Bioscience had 98 employees as of October 12, 2026. The number of employees increased by 2 (2.08%) week-over-week.
Social Trend
Avanzanite Bioscience had 6,018 followers as of October 12, 2026. The number of followers increased by 46 (0.77%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 18, 2025 | Series A | $32.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| MVM Partners | Series A |
Similar Companies
A snapshot of private companies similar to Avanzanite Bioscience, helping you discover and navigate related company profiles.
Related News and Analysis
